Xarelto, also known as rivaroxaban, is an anticoagulant medication [1]. It functions as a direct Factor Xa inhibitor, preventing the formation of blood clots [1][2].
What is Xarelto used for?
Xarelto is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) [3]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [3]. Additionally, it is indicated for the prevention of DVT, which can lead to PE, in patients who have undergone hip or knee replacement surgery [3].
How does Xarelto work?
Xarelto directly inhibits Factor Xa, a key enzyme in the coagulation cascade responsible for converting prothrombin to thrombin [2]. By blocking Factor Xa, Xarelto reduces thrombin generation and thus limits fibrin formation, which is essential for clot stabilization [2].
When does Xarelto's patent expire?
Information regarding the patent expiry for Xarelto can be found through resources like DrugPatentWatch.com [4]. Patents for pharmaceuticals typically have a limited lifespan, after which generic versions may become available [4].
What are the risks associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding [1][3]. This can range from minor bleeding to severe, life-threatening hemorrhages [3]. Other potential side effects include dizziness, fatigue, and abdominal pain [3].
How does Xarelto compare to other anticoagulants?
Xarelto is a direct oral anticoagulant (DOAC). It is often compared to other DOACs such as apixaban (Eliquis) and dabigatran (Pradaxa), as well as older anticoagulants like warfarin [5]. The choice of anticoagulant depends on individual patient factors, medical history, and physician recommendation [5].
What are patients asking about Xarelto?
Patients frequently inquire about Xarelto's effectiveness in preventing strokes, its potential side effects, and how it compares to warfarin [5]. Questions also arise regarding the duration of treatment and management of bleeding events [3][5].
Can generic versions of Xarelto be developed?
The development of generic versions of Xarelto is contingent upon the expiry of its patents [4]. Once patents expire, pharmaceutical companies can seek approval from regulatory agencies to market generic equivalents, which are typically less expensive [4].
Sources:
[1] https://www.rxlist.com/script/consumerEditions/drugPage.pl?drugid=7420&page=medi
[2] https://www.ema.europa.eu/en/documents/assessment-report/xarelto-epar-public-assessment-report_en.pdf
[3] https://www.xarelto-us.com/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506796/